ArticleInfection and drug resistance2024
Multidrug-Resistant
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Biofilm Formation, Virulence-Associated Genes, and Antimicrobial Resistance inMicroorganisms · 2026Article
- Isolation and characterization of a bacteriophage targeting Proteus mirabilis for use in culture media.BMC microbiology · 2026Article
- Draft genome sequencing of Proteus mirabilis strain Indica (ST286) reveals antimicrobial resistance and virulence determinants.BMC microbiology · 2026Article
- Phage PM16 Therapy Induce Long-Term Protective Immunity AgainstPathogens (Basel, Switzerland) · 2026Article
- Antimicrobial Resistance Profile of Urinary Bacterial Isolates from Hospitalized Companion Dogs Reveals a Potential Public Health Risk in South Korea.Veterinary sciences · 2026Article
- Characterization ofMicrobiology spectrum · 2026Article
- Genomic epidemiology of multidrug-resistant and ESBL-producing Proteus mirabilis in a military referral hospital in Ethiopia.PloS one · 2026Article
- A Novel Therapeutic Approach: Phage andScientifica · 2026Article
- Zoonotic Risks ofMicroorganisms · 2025Review
- Molecular Surveillance of ESBL and Carbapenemase Genes in Gram-Negative Bacterial Pathogens Isolated from Various Clinical Samples Collected from Northern Region of United Arab Emirates.Microorganisms · 2025Article
- Proteus mirabilis in ICU Patients: Prevalence, Risk Factors, and Future Expectations of Bloodstream Infections.Cureus · 2025Article
- Emergence of β-lactamase-producingBiotechnology notes (Amsterdam, Netherlands) · 2025Article
- Medical Device-Associated Biofilm Infections and Multidrug-Resistant Pathogens.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: A total of 598 Results: Pan-drug-resistant isolates were identified in 2019 (n = 6), although multi- and extensively drug-resistant isolate frequencies were greatest among all patients in 2019. The highest susceptibility levels were observed for piperacillin-tazobactam, carbapenems, and cephalosporins antibiotics. In contrast, Cephalothin, trimethoprim-sulfamethoxazole, and ampicillin had the lowest susceptibilities. Urine infections with a positive culture of Conclusion: Hospitalized patients are at risk of fatal consequences due to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.